Jan A. Burger
0000-0002-6177-7572
Publication & Citation Trends
Most Cited Works
Publications
843 total
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy
Cited by 0
Semantic Scholar
Clinical, genetic, and familial features of POT1 tumor predisposition syndrome
Cited by 0
Semantic Scholar
Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia
Cited by 0
Semantic Scholar
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.
Cited by 5
Semantic Scholar
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD.
Cited by 3
Semantic Scholar
PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL. OA
Cited by 0
Semantic Scholar
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma PDF
Cited by 461
OpenAlex
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study PDF
Cited by 453
OpenAlex
Chapter 2 The CLL Cell Microenvironment
Cited by 0
Semantic Scholar
Research Topics
Chronic Lymphocytic Leukemia Research
(632)
Lymphoma Diagnosis and Treatment
(317)
Chronic Myeloid Leukemia Treatments
(197)
Immunodeficiency and Autoimmune Disorders
(146)
Acute Lymphoblastic Leukemia research
(120)
Frequent Co-Authors
Affiliations
Scripps Research Institute
La Jolla Institute for Immunology
Scripps Health
The University of Texas MD Anderson Cancer Center
Vita-Salute San Raffaele University